GFM
RXRX icon

GF Fund Management’s Recursion Pharmaceuticals RXRX Stock Holding History

GF Fund Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.3K Buy
11,506
+1,402
+14% +$5.42K ﹤0.01% 439
2025
Q4 		$41.3K Buy
10,104
+911
+10% +$4.51K ﹤0.01% 421
2025
Q3 		$44.9K Sell
9,193
-582
-6% -$3.06K ﹤0.01% 405
2025
Q2 		$49.5K Hold
9,775
– – ﹤0.01% 415
2025
Q1 		$51.7K Buy
9,775
+1,759
+22% +$12.8K ﹤0.01% 417
2024
Q4 		$54.2K Buy
+8,016
New +$53.9K ﹤0.01% 384

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GF Fund Management's RXRX Position: Q1 2026 in Review

GF Fund Management increased its Recursion Pharmaceuticals (RXRX) stake by 14% in Q1 2026, buying an estimated $5.42K and bringing the position to 11,506 shares worth $35.3K. The position accounts for ﹤0.01% of the portfolio, ranked #439.

GF Fund Management first reported a position in RXRX in Q4 2024 and has held it in 6 quarters since. The position peaked at $54.2K in Q4 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • GF Fund Management held 11,506 shares of Recursion Pharmaceuticals worth $35.3K as of Q1 2026.
  • GF Fund Management bought 1,402 Recursion Pharmaceuticals shares in Q1 2026, an estimated $5.42K.
  • Recursion Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #439 holding.
  • GF Fund Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Recursion Pharmaceuticals position peaked at $54.2K in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.